In this study, we aimed to investigate the apoptotic effects of topical antiglaucoma medications on the conjunctival epithelium.
Methods
A total of 65 patients were included in the study. Thirty patients were included in the first group who had received antiglaucomatous therapy before trabeculectomy. In the second group, 20 patients who had received no drugs before trabeculectomy were included, while the third group underwent only cataract surgery as control. During the surgery, 2 × 4 mm conjunctival samples were harvested from the upper bulbar conjunctiva. The mean apoptosis rate was calculated by determining apoptosis at conjunctival epithelium using the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) method.
Results
The mean apoptosis rate was 0.537 ± 0.369 (0.026 ± 0.962) in group 1, 0.139 ± 0.162 (0.005 ± 0.676) in group 2, and 0.078 ± 0.035 (0.035 ± 0.142) in the control group (group 3). The mean apoptosis rate was significantly higher in the first group than the other 2 groups (p = 0.0001).
Conclusions
Apoptotic effects of topical antiglaucoma drugs on the conjunctival epithelial cells were found. However, our results revealed that the number of medications, duration of medication, and type of glaucoma had no effect on the apoptotic effect.
QuigleyH.A., AddicksE.M., GreenW.R., MaumeneeA.E.. Optic nerve damage in human glaucoma. II. The site of injury and susceptibility to damage.Arch Ophthalmol1981; 99: 635–49.
2.
The Glaucoma Laser Trial Research Group.The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines.Ophthalmology1990; 97: 1403–13.
Van BuskirkE.M.. Adverse reactions from timolol administration.Ophthalmology1980; 87: 447–50.
5.
SherwoodM.B., GriersonI., MillarL., HitchingsR.A.. Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon's capsule in glaucomatous patients.Ophthalmology1989; 96: 327–35.
6.
BaudouinC.. Side effects of antiglaucomatous drugs on the ocular surface.Curr Opin Ophthalmol1996; 7: 80–6.
7.
DebbaschC., BrignoleF., PisellaP.J., WarnetJ.M., RatP., BaudouinC.. Quaternary ammoniums and other preservatives' contribution in oxidative stress and apoptosis on Chang conjunctival cells.Invest Ophthalmol Vis Sci2001; 42: 642–52.
8.
De Saint JeanM., BrignoleF., BringuierA.F., BauchetA., FeldmannG., BaudouinC.. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells.Invest Ophthalmol Vis Sci1999; 40: 619–30.
9.
DebbaschC., PisellaP.J., De Saint JeanM., RatP., WarnetJ.M., BaudouinC.. Mitochondrial activity and glutathione injury in apoptosis induced by unpreserved and preserved beta-blockers on Chang conjunctival cells.Invest Ophthalmol Vis Sci2001; 42: 2525–33.
10.
BroadwayD.C., GriersonI., O'BrienC., HitchingsR.A.. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile.Arch Ophthalmol1994; 112: 1437–45.
11.
BroadwayD.C., GriersonI., O'BrienC., HitchingsR.A.. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery.Arch Ophthalmol1994; 112: 1446–54.
KerrJ.F., WyllieA.H., CurrieA.R.. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics.Br J Cancer1972; 26: 239–57.
14.
SarasteA., PulkkiK.. Morphologic and biochemical hallmarks of apoptosis.Cardiovasc Res2000; 45: 528–37.
15.
MajnoG., JorisI.. Apoptosis, oncosis, and necrosis. An overview of cell death.Am J Pathol1995; 146: 3–15.
16.
GavrieliY., ShermanY., Ben-SassonS.A.. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.J Cell Biol1992; 119: 493–501.
17.
TakahashiN.. [Cytotoxicity of preservatives on cultured human conjunctival cells (author's transl).]Nihon Ganka Gakkai Zasshi1980; 84: 1171–6.
18.
TakahashiN.. [Cytotoxic effects of antiglaucoma agents on cultured human conjunctival cells (author's transl).]Nihon Ganka Gakkai Zasshi1981; 85: 1046–52.
19.
DoğanA.S., OrhanM., SöylemezoğluF., IrkeçM., BozkurtB.. Effects of topical antiglaucoma drugs on apoptosis rates of conjunctival epithelial cells in glaucoma patients.Clin Experiment Ophthalmol2004; 32: 62–6.
20.
AriciM.K., AriciD.S., TopalkaraA., GülerC.. Adverse effects of topical antiglaucoma drugs on the ocular surface.Clin Experiment Ophthalmol2000; 28: 113–7.
21.
DerousD., de KeizerR.J., de Wolff-RouendaalD., SoudijnW.. Conjunctival keratinisation, an abnormal reaction to an ocular beta-blocker.Acta Ophthalmol1989; 67: 333–8.
22.
HerrerasJ.M., PastorJ.C., CalongeM., AsensioV.M.. Ocular surface alteration after long-term treatment with an antiglaucomatous drug.Ophthalmology1992; 99: 1082–8.
23.
NuzziR., FinazzoC., CerrutiA.. Adverse effects of topical antiglaucomatous medications on the conjunctiva and the lachrymal response.Int Ophthalmol1998; 22: 31–35.
24.
AriciM.K., DemircanS., TopalkaraA., GülerC., AkerH., AriciD.S.. Effect of conjunctival structure and inflammatory cell counts on intraocular pressure after trabeculectomy.Ophthalmologica1999; 213: 371–5.
25.
YalvaçI.S., GedikoğluG., KaragözY.. Effects of antiglaucoma drugs on ocular surface.Acta Ophthalmol Scand1995; 73: 246–8.
26.
BaudouinC., HamardP., LiangH., Creuzot-GarcherC., BensoussanL., BrignoleF.. Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term.Ophthalmology2004; 111: 2186–92.
27.
BaudouinC., LiangH., HamardP.. The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways.Ophthalmology2008; 115: 109–15.
28.
BursteinN.L.. The effects of topical drugs and preservatives on the tears and corneal epithelium in dry eye.Trans Ophthalmol Soc UK1985; 104: 402–9.
29.
BrasnuE., Brignole-BaudouinF., RianchoL., GuenounJ.M., WarnetJ.M., BaudouinC.. In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line.Curr Eye Res2008; 33: 303–12.
30.
BursteinN.L.. Preservative cytotoxic threshold for benzalkonium chloride and chlorhexidine digluconate in cat and rabbit corneas.Invest Ophthalmol Vis Sci1980; 19: 308–13.
31.
FisherA.A.. Allergic contact dermatitis and conjunctivitis from benzalkonium chloride.Cutis1987; 39: 381–3.
32.
BaudouinC., GarcherC., HaouatN., BronA., GastaudP.. Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma.Ophthalmology1994; 101: 454–60.
33.
De Saint JeanM., BrignoleF., BringuierA.F., BauchetA., FeldmannG., BaudouinC.. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells.Invest Ophthalmol Vis Sci1999; 40: 619–30.
34.
De Saint JeanM., DebbaschC., BrignoleF., RatP., WarnetJ.M., BaudouinC.. Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells.Curr Eye Res2000; 20: 85–94.
35.
HamardP., BlondinC., DebbaschC., WarnetJ.M., BaudouinC., BrignoleF.. In vitro effects of preserved and unpreserved antiglaucoma drugs on apoptotic marker expression by human trabecular cells.Graefes Arch Clin Exp Ophthalmol2003; 241: 1037–43.
36.
IhanA., CvenkelB.. Conjunctival epithelium expression of HLA-DR in glaucoma patients and its influence on the outcome of filtration surgery.Br J Ophthalmol2000; 84: 648–50.
